MIT Team Shows T-Cell Buoyant Mass Beats TMB at Predicting Immunotherapy Response

A clinical study of 28 patients with melanoma has shown that measuring the buoyant mass of T cells predicts response to immune checkpoint blockade (ICB) more accurately than tumor mutational burden (TMB), the standard molecular predictor. Researchers at the Massachusetts Institute of Technology (MIT) reported the result as the first clinical validation of a physical marker — cell mass — as a decision tool in cancer immunotherapy.

The finding carries weight beyond oncology. According to the MIT team, the same measurement could gauge the productivity of cell cultures used in gene therapy manufacturing, giving process-development groups a fast, non-molecular read on cell fitness before activation and expansion.

Jiaquan Yu, PhD, a research scientist in microfluidic engineering and cancer immunology at MIT, led the technical description of the work. "We've wanted to show people this is a new physical marker that predicts the fate of the T cells," Yu said. "By fate, we mean we measure the naïve state of the T cells and get an indication of how they will behave after activation."

How the measurement works

The team used suspended microchannel resonator (SMR) technology. The instrument carries a vibrating sensor with an embedded microfluidic channel; as individual T cells pass through, the sensor registers each cell's buoyant mass relative to water.

From that single physical quantity, the researchers calculated an immune fitness score for the cells — an estimate of whether they were likely to activate and fight cancer under ICB treatment. The logic is direct: heavier T cells hold more capacity for protein production.

"For T cells, being in the heavier group suggests you're better equipped to produce proteins," Yu said. "And that capacity gives us an indication of the fitness of the cells and their ability to respond after activation."

What did the clinical study show?

The study enrolled 28 patients with melanoma receiving ICB therapy. In that cohort, buoyant mass measurement outperformed TMB at predicting which patients would respond to treatment, Yu explained.

The sample size is modest, and the source report does not specify the performance gap between the two methods in numeric terms, such as sensitivity or predictive values. The comparison rests on a single 28-patient melanoma cohort; broader cancer types and larger validation sets remain untested in the reported data.

Why a physical marker, and why now?

Yu argued the field's biomarker pipeline has overlooked simple physical signatures while concentrating on nucleic-acid assays.

"People are underestimating simple non-molecular signatures, such as mass, volume, and density, as we're all focused on biomarkers focused on genes and RNA," Yu said. "What we're showing here is that mass gives a result that integrates a lot of information."

That integration argument matters for R&D planning. A single SMR pass yields a functional readout of cellular state without sequencing, staining, or transcriptomic processing — an attractive profile for quality-control steps in cell therapy manufacturing, where rapid assessments of starting material and culture health drive batch decisions and cost.

What comes next

The MIT group sees two application tracks: predicting cancer cell sensitivity to ICB in the clinic, and monitoring cell culture productivity in gene therapy production. Both rest, for now, on one 28-patient study and instrument-level measurements from a single lab; independent replication and larger cohorts will determine whether buoyant mass moves from proof of concept into standard workflow.